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Background: The structure and function of GPR35 are not understood.
Results: Using a GPR35 activated state molecular model, we identified crucial amino acid residues required for ligand activation
using ␤-arrestin trafficking, ERK1/2 activation, and calcium imaging.
Conclusion: Arginines in TMH3-4-5-6 affected agonist signaling.
Significance: Identification of residues for GPR35 agonist signaling is critical for the design of ligands with improved potency.
GPR35 is a G protein-coupled receptor expressed in the
immune, gastrointestinal, and nervous systems in gastric carcinomas and is implicated in heart failure and pain perception.
We investigated residues in GPR35 responsible for ligand activation and the receptor structure in the active state. GPR35 contains numerous positively charged amino acids that face into the
binding pocket that cluster in two distinct receptor regions,
TMH3-4-5-6 and TMH1-2-7. Computer modeling implicated
TMH3-4-5-6 for activation by the GPR35 agonists zaprinast and
pamoic acid. Mutation results for the TMH1-2-7 region of
GPR35 showed no change in ligand efficacies at the K1.32A,
R2.65A, R7.33A, and K7.40A mutants. However, mutation of
arginine residues in the TMH3-4-5-6 region (R4.60, R6.58,
R3.36, R(164), and R(167) in the EC2 loop) had effects on signaling for one or both agonists tested. R4.60A resulted in a total
ablation of agonist-induced activation in both the ␤-arrestin
trafficking and ERK1/2 activation assays. R6.58A increased the
potency of zaprinast 30-fold in the pERK assay. The R(167)A
mutant decreased the potency of pamoic acid in the ␤-arrestin
trafficking assay. The R(164)A and R(164)L mutants decreased
potencies of both agonists. Similar trends for R6.58A and
R(167)A were observed in calcium responses. Computer modeling showed that the R6.58A mutant has additional interactions
with zaprinast. R3.36A did not express on the cell surface but
was trapped in the cytoplasm. The lack of surface expression of
R3.36A was rescued by a GPR35 antagonist, CID2745687. These
results clearly show that R4.60, R(164), R(167), and R6.58 play
crucial roles in the agonist initiated activation of GPR35.

G protein-coupled receptors (GPCRs)4 represent the largest
target for current and future therapeutic agents. GPR35 is a

class A GPCR that is expressed in the immune and gastrointestinal systems, dorsal root ganglia, cerebellum, and brain (Fig. 1)
(1– 4). GPR35 regulation appears to have profound physiological and pathophysiological implications (5–10); thus, great
efforts have been made to identify compounds that regulate
GPR35 (4, 5, 11–14). Kyneurinic acid (15) and lysophosphatidic
acid (14), both anions, have been reported to be GPR35 endogenous ligands. Pamoic acid (5), zaprinast (4), 5-nitro-2-(3phenylpropylamino) benzoic acid (11), nedocromil sodium
(Tilade) (13), and cromolyn sodium (Intal) (13) have been
reported to be GPR35 agonists, whereas methyl-5-[(tert-butylcarbamothioylhydrazinyl-idene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687) has been reported to be an
antagonist at GPR35 (5). With the exception of zaprinast, the
GPR35 agonist ligands reported to date are mono- or dicarboxylic acids that would be ionized at physiological pH. Perhaps, not surprisingly then, the GPR35 sequence contains
numerous positively charged amino acids that face into the
binding pocket. These residues cluster in two distinct receptor
regions, the TMH3-4-5-6 region and the TMH1-2-7 region of
GPR35 (Fig. 1). In work reported here, we have used a combination of modeling and mutation studies to probe the importance of these positively charged residues to the binding of two
GPR35 agonists, zaprinast and pamoic acid (see drawings in Fig.
2). These studies suggest that residues in the TMH3-4-5-6
region of GPR35 play crucial roles in the agonist-binding initiated activation of this receptor.

EXPERIMENTAL PROCEDURES
Materials—DMEM, Hanks’ balanced salt solution and FBS
were purchased from Cellgro, Mediatech, Inc., and Hyclone.
Pamoic acid and poly-D-lysine were purchased from Sigma.
Zaprinast was purchased from Tocris. Anti-phospho ERK antibodies were purchased from Cell Signaling. Anti-HA mouse
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␤-arrestin2-green fluorescent protein; ␤2-AR, ␤2-adrenergic receptor;
CID2745687, methyl-5-[(tert-butylcarbamothioylhydrazinyl-idene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate; CM, conformational
memories; TMH, transmembrane helix; CI, confidence interval; SP, standard
precision; IC, intracellular; EC, extracellular; ER, endoplasmic reticulum.
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FIGURE 1. Schematic representation of human GPR35 receptor structure and its seven transmembrane domain regions. The TMH residue highlighted
in blue in each TMH is the most highly conserved residue among class A GPCRs in that helix.

FIGURE 2. Structures of pamoic acid and zaprinast.
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monoclonal antibody was purchased from Covance. Alexa 568
goat anti-mouse antibody, Zeocin, and Lipofectamine 2000 were
purchased from Invitrogen. IRDye 800-conjugated anti-mouse
IgG was from LI-COR. HA-GPR35a plasmid and cell line were
provided by the Duke University GPCR Assay Bank. All other
reagents were obtained from Sigma or other standard sources.
Plasmids, Mutagenesis, Transfection, and Cell Culture—
␤-Arrestin2-green fluorescent protein (␤arr2-GFP) (Renilla) is
described previously (5, 16). The R3.36A, A4.59G, R4.60A,
R6.58A, R(164)A/L, and K7.40A mutants were constructed
using the QuikChange site-directed mutagenesis kit (Stratagene) based on the 3⫻ HA-tagged human GPR35a in the
pcDNA3.1 vector. Synthetic oligonucleotide mutagenic primers were typically 25–35 base pairs long (with 12–17 base pairs
on either side of the desired mismatch region). DNA sequencing was subsequently used to ascertain the presence of the
designed mutation. Stably transfected U2OS cell lines were created by transfection with wild-type or mutant human GPR35
together with ␤arr2-GFP plasmid by using the Lipofectamine
2000 reagent (Invitrogen) following the manufacturer’s protocol. Clones were selected in growth medium containing G418
(0.4 mg/ml) and Zeocin (0.2 mg/ml) (Invitrogen) as described
previously (17). Stable cell lines were then maintained in G418
(0.2 mg/ml) and Zeocin (0.1 mg/ml). U2OS and HEK293 cells
transiently transfected with R3.36A were used for experiments
2 days after transfection.
Immunocytochemistry and Microscopy—The expression of
wild-type and mutant GPR35 receptors was examined by
immunostaining of cells with HA monoclonal antibodies. To
achieve surface receptor staining, cells grown on coverslips
were incubated over ice for 40 min with a 1:100 dilution of
mouse monoclonal anti-HA antibody in blocking buffer (3%
BSA in PBS). This was followed by appropriate washes and
40-min incubation with a 1:1500 dilution of Alexa Fluor 568
goat anti-mouse secondary antibody. Cells were then fixed with
4% paraformaldehyde for 20 min at room temperature followed
by three washes with PBS. The total receptor immunostaining
VOLUME 289 • NUMBER 6 • FEBRUARY 7, 2014
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was done by fixing then permeabilizing cells with 0.2% Triton
X-100 before the primary HA antibodies (1:500) application.
Following the staining, glass coverslips were mounted on slides
and were imaged on a (Nikon E800) fluorescence microscope
using a 40⫻ oil objective and 488-nm excitation for GFP. Coimmunostaining of R3.36A and calreticulin (18) was done by
co-applying mouse anti-HA antibodies (1:500) and rabbit anticalreticulin antibodies (Cell Signaling; 1:200) followed by Alexa
Fluor 568 goat anti-mouse secondary antibody (1:1500) and
Alexa Fluor 488 goat anti-rabbit secondary antibody (1:1000).
␤-Arrestin Assay for Determining Receptor Responsiveness—
The ␤-arrestin assay was described previously (5). Briefly, stable
cell lines were plated onto poly-D-lysine-coated coverslips in
24-well plates. Cells were maintained at 37 °C in 5% CO2 until
ready for experiments (80–85% confluent) and washed once with
Hanks’ balanced salt solution before drug application, and experiments were performed in Hanks’ balanced salt solution. Agoniststimulated redistribution of ␤arr2-GFP was assessed following
drug treatment for 40 min at room temperature. Cells were fixed
and imaged as described above. Quantification of ␤arr2-GFP
aggregates was described previously (5). Concentration-effect
curves for agonist-mediated receptor activation were analyzed by
nonlinear regression techniques using GraphPad Prism 5.0 software (GraphPad), and data were fitted to sigmoidal dose-response
curves to obtain EC50 or IC50 values. Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s
post-test or two-tailed unpaired Student’s t test. p values of ⬍0.05
are considered significant.
In-Cell Western Assay for ERK Activity—The assay was
described previously (5). Briefly, cells were grown to confluence
in 96-well plates and serum-starved overnight prior to assay.
Following the 20-min agonist treatment at room temperature,
the medium was removed, and 4% paraformaldehyde in PBS
was added to fix cells for 1 h at room temperature. Cells were
then permeabilized by 0.1% Triton X-100 in PBS for five
washes, 10 min per wash. LI-COR blocking buffer was added,
and samples were shaken on a rotator for 1 h. Primary antibodies against phosphor-ERK1/2 (Cell Signaling Technology;
1:100) were applied for 2 h, and then secondary antibodies goat
anti-rabbit 800CW (1:800) were applied overnight in a cold
room. Sapphire700 (LI-COR, 1:1000) and DRAQ5 (Biostatus
Limited, 1:2000) were added together with the secondary antibodies for normalization. The plate was dried and then scanned
using a LI-COR Odyssey Infrared Imager set at 169 M resolution, 3 focus offset, and 4.5– 6 intensity. Data were analyzed
using Excel and Prism 5.0 software.
Calcium Imaging—Intracellular Ca2⫹ measurements were
performed as described previously (19). Briefly, GPR35 and
mutant stable U2OS cells were loaded with fura-2/AM and
mounted in an open bath chamber (RP-40LP; Warner Instruments, Hamden, CT) on the stage of an inverted microscope
Nikon Eclipse TiE (Optical Apparatus Co., Ardmore, PA).
Fura-2/AM fluorescence (emission ⫽ 510 nm) following alternate excitation at 340 and 380 nm was acquired at a frequency
of 0.25 Hz. Images were acquired and analyzed using Nikon
NIS-Elements AR 3.1 software (Optical Apparatus Co.). The
ratio of the fluorescence signals (340/380 nm) was converted to
Ca2⫹ concentrations.
FEBRUARY 7, 2014 • VOLUME 289 • NUMBER 6

Quantification of Receptor Surface Expression—We used
average fluorescent signal intensity analysis of surface receptor
staining on the whole cell surface to measure total expression
levels (20). Within the confines of the demarcation of the cell
area in each image, we measured the average fluorescent signal
to sample receptor expression level by using ImageJ software
(1.47v; National Institutes of Health). Sampling the protein
expression level of receptors in the easily definable cell area in
the images provides an estimate of the total receptor expression
that can be used to compare WT and mutant expression levels.
Modeling of GPR35 Using GPCR Crystallization Data—During the development of this model, several GPCRs have been
crystallized, including rhodopsin (21–23), opsin (24) the ␤2-adrenergic receptor (␤2-AR) (25–27), the ␤1-adrenergic receptor
(28), the A2-adenosine receptor (29), and the CXCR4 receptor
(30). The model of the activated form of GPR35 is based on the
2.4 Å resolution crystal structures of the ␤2-AR (25). The initial,
canonical comparison of GPR35 with other class A GPCRs was
based on a sequence comparison. The GPR35 sequence was
aligned with the sequences of rhodopsin, ␤2-AR, A2-adenosine,
and the cannabinoid CB1 and CB2 receptors, using highly conserved residues as alignment guides as done previously for the
CB1 (31) and CB2 (32) receptors. GPR35 contains many of the
highly conserved class A residue patterns in TMHs 1, 2, 3, 4, 5
(N1.50, D2.50, and (E)DRY motif in TMH3, C3.25, W4.50, and
P5.50). However, there are some notable sequence variations
that may alter the geometry of one or more helices in GPR35 as
described below.
Conformational Memories (CM) Technique for Calculating
TMH Conformation—For TMH 1, 2, 4, 5, 6, and 7, a series of
possible, sequence-dictated conformations that deviate from
the ␤2-AR template were calculated using the CM Monte Carlo/simulated annealing technique (33, 34). The CM technique
uses multiple Monte Carlo/simulated annealing random walks
employing the CHARMM all atom force field (35) in a distancedependent dielectric at 310 K. With this technique, nearly all
dihedrals and bond angles are defined as variable, with various
restrictions. Bond angle variation ranges were defined as either
⫾8° for default bond angles or ⫾15° for side chain angles involving polar hydrogens (i.e., C-O-H: Ser, Thr, Tyr) or the flexible
C-S-C bond angle in methionine. The backbone dihedrals ⌽, ⌿,
and  had standard dihedral variation ranges of ⫾10°, ⫾10°,
and ⫾20°, respectively, and the side chain dihedrals had full
range of motion. If the sequence contained a known helix
deforming residue such as proline, serine (36), threonine (36),
or glycine, a larger variation range of up to ⫾50° on the ⌽ and ⌿
was implemented to allow for increased flexibility. An ideal
helix (⌽ ⫽ ⫺62.9° and ⌿ ⫽ ⫺41.6°) with the GPR35 sequence
for each TMH was built, and a minimum of 105 conformers
were generated for each GPR35 helix independently.
TMH1 in GPR35 has three nonconsecutive glycines located
at positions 1.34, 1.39, and 1.46. An ideal helix with the GPR35
sequence was built, and three independent calculations were
performed with increased flexibility of the backbone (⌽/⌿ of ⫾
50°) at the residues mentioned above.
TMH2 in GPR35 has a proline that is shifted by one residue
intracellularly as compared with the ␤2-AR sequence: P2.59 in
the ␤2AR and P2.58 in GPR35. An ideal helix with the GPR35
JOURNAL OF BIOLOGICAL CHEMISTRY
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sequence was built, and a flexible region (⌽/⌿ ⫾ 50°) was
implemented into the P2.58 to L2.54 region to evaluate the
flexibility at this proline position.
TMH4 in GPR35 lacks the conserved proline located at the
extracellular end of the ␤2-AR TMH4, but it contains a potential helix deforming motif, GS (G4.55–S4.56). Two independent conformational searches were performed from an ideal
helix starting structure to determine the impact of this motif.
The first explored only the increased flexibility of the backbone
at G4.55 (⌽/⌿ of ⫾ 50°), and the second explored both backbone flexibility and 1 of S4.56 restrained to g(⫺) (36).
TMH5 in GPR35 has two proline residues; the conserved
proline at position 5.50 and an additional proline at 5.43. The
flexibly of the proline kink of the conserved proline (G5.45 to
P5.50) was restricted to empirically based backbone dihedral
ranges, and the proline kink of nonconserved proline (S5.39 to
P5.42) was given increased backbone flexibility (⌽/⌿ of ⫾ 50°).
TMH6 in GPR35 lacks the highly conserved CWXP motif but
has the conservative substitution, CFXP. The importance of
exploring the possible conformational space of TMH6 lies in
the documented changes in TMH6 conformation that occur
when a class A GPCR is activated (37). In ␤2-AR and rhodopsin,
the most dramatic structural change associated with activation
is the conformational change in TMH6 about the highly conserved CWXP hinge region (38 – 45). Two independent conformational searches were performed with an identical, ideal helix
starting structure to be representative of either an R or R* state.
The flexibility of the backbone of the conserved proline kink
region (V6.46 to P6.50) was restricted to the empirically based
ranges of the antagonist bound GPCR crystal structures for the
R state and allowed full flexibility (⌽/⌿ of ⫾ 50°) for the R*
state. G6.54 was also considered flexible ((⌽/⌿ of ⫾ 50°) in both
calculations.
TMH7 in GPR35 lacks the conserved P7.50 in the NPXXY
motif and has the nonconservative substitution of DAXXY. To
determine whether the GPR35 TMH7 sequence may suggest a
flexible region within the same area as the conserved proline
kink region, an increased flexibility (⌽/⌿ ⫾ 50°) was introduced in the region of C7.46 to A7.50. The TMH7 conformation chosen for bundle creation was one that allowed D7.43 to
hydrogen-bond to Y3.32. This interaction is found in the
CXCR4 crystal structure (30).
Construction of the GPR35 Inactive State TMH Bundle—The
conformers generated by the CM calculations were used to
construct the TMH region of the receptor. The receptor was
assembled by aligning the intracellular regions of TMHs 1, 2, 4,
and 5–7 with the ␤2-AR template. In the R model, R3.50 and
T6.30 form a hydrogen bond that mimics the R3.50/D or E6.30
ionic lock common in class A GPCRs. The bundle was then
pulled apart 3 Å and energy-minimized for 1500 iterations utilizing the OPLS2005 all atom force field in Macromodel 9.1
(Schrodinger Inc., Portland, OR) employing a distance-dependent dielectric with extended cutoffs (nonbonded, 8.0 Å; electrostatic, 20.0 Å; and hydrogen bonding, 4.0 Å) and the PolakRibiere conjugate minimization scheme to pack the TMHs and
relieve side chain clashes. A harmonic constraint was placed on
the backbone (, , and ) of 500 kj/mol to maintain helicity.

3628 JOURNAL OF BIOLOGICAL CHEMISTRY

For the inactive (R) bundle, several highly conserved residue
side chain dihedrals were restrained to crystal structure ranges.
Modeling of the Intra/Extracellular Loops and Receptor
Termini—Modeler 8.2 (46, 47) was used to generate the N and
C termini (Met-1 to Pro-16 and Pro-293 to Ala-309, respectively) and the intra- and extracellular loops (IC1: Arg-48 to
Glu-54, IC2: Pro-121 to Ser-129, IC3: Ala-199 to Thr-212, EC1:
Asp-82 to Thr-86, EC2: Leu-153 to His-168, EC3: Gly-244 to
Ala-247). A restrictive distance was implemented between Cys(162), located on the EC2 loop, and Cys-3.25(89) to emulate the
class A highly conserved disulfide bridge between residues at
these positions. A restricted distance was also implemented
between C(8) in the N terminus and C7.25(248) at the EC end of
TMH7 to emulate the disulfide bridge seen in the CXCR4 crystal structure (30). An EC-2 loop conformation was selected that
had the second residue past the disulfide bridge (R(164)) pointing into the bundle as this is seen in the ␤2-AR (25–27) and
other x-ray crystal structures. With the TMHs frozen, the final
loops were energy-minimized to a gradient of 0.01 kcal/mol in a
high dielectric of 80 using the same force field, cutoffs, and
conjugate method described earlier.
Modeling of the Human GPR35 R* Receptor—To create an
activated GPR35 model (R*), The EC2 and IC3 loops were
removed, and a second TMH6 conformer was chosen that was
straighter than TMH6 in the R model. This conformer was
chosen so that no hydrogen bond was broken. With the loops
and termini frozen, the TMH region was energy-minimized for
500 iterations in a distance-dependent dielectric utilizing the
same force field, cutoffs, and conjugate method described earlier, with a harmonic constraint was placed on the backbone (,
, and ) of 1000 kj/mol to maintain helicity. The EC2 and IC3
loops were then modeled as described above, including the distance restraint in the EC2 loop to mimic the conserved disulfide
bridge. The final loops were then energy-minimized, as
described above, to a gradient of 0.01 kcal/mol in a high dielectric of 80.
Modeling of the Human R6.58A Mutant GPR35 R* Receptor—
To create the R6.58A R* receptor model, residue 6.58 in the WT
R* bundle was mutated to Ala, and the bundle was reminimized
using the same protocol as described above.
Ligand Conformational Analysis—Complete conformational
analyses were performed on pamoic acid and zaprinast.
Because pamoic acid (pKa1 ⫽ 2.51, pKa2 ⫽ 3.1) is a dianion at
physiological pH (48), conformational analyses were performed
on the dianionic form. Zaprinast (Fig. 2) can exist in several
tautomeric forms, so conformational analyses were performed
for each tautomer.
Hartree-Fock ab initio calculations at the 6 –31⫹G* level as
encoded by Spartan ’08 (Wavefunction, Inc., Irvine, CA) were
performed for each compound. For each comformational
search, local energy minima were identified by the rotation of
subject dihedrals 360° in 60° increments (6-fold search), followed by a Hartree-Fock 6 –31⫹G* energy minimization of
each rotamer generated. For this reason, the energy minimum
of each tautomeric form was assessed at the 6 –31⫹G* level.
Pamoic acid conformational analyses were performed in vacuo
and using a SM8 water solvation model as implemented in
Spartan ’08 (Wavefunction, Inc.).
VOLUME 289 • NUMBER 6 • FEBRUARY 7, 2014
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Docking of Ligands—The global minimum energy conformer
of pamoic acid (dianion) and the global minimum energy conformer of the 2,6-dihydro tautomeric state of zaprinast were
used for docking studies (see numbering system in Fig. 2).
Because of recent experimental data (49), Y3.32(96) was used as
the primary interaction site for zaprinast, and two arginine residues located near the binding pocket (R3.36(100) and
R4.60(151)) were used as primary interactions for the pamoic
acid (dianion). Initially, each compound was manually docked
in the binding site of GPR35 R* (or R6.58A R*) model.
Ligand/Receptor Minimization—The ligand-receptor complexes were minimized using an OPLS2005 all atom force in
Macromodel 9.9 (Schrodinger Inc.). An extended cutoff (nonbonded, 8.0 Å; electrostatic, 20.0 Å; hydrogen bonding, 4.0 Å)
was used in each stage of the calculation. The minimization was
broken into two stages: 1) the minimization of the ligand and
the TM regions. The first step consisted of 1250 steps of conjugate gradient minimization using a distance-dependent dielectric. Harmonic constraints of 1000 kcal/mol were placed on
select dihedrals of the ligand to maintain conformational similarity to the low energy conformer calculated at the HartreeFock 6 –31⫹G* level of theory as the receptor. The ligand
restraints were released for the last 250 steps to allow the ligand
to adapt to the optimized binding pocket. The EC and IC loop
regions were frozen during this stage. 2) The extracellular and
intracellular loops were minimized for 500 steps in a generalized born/surface area continuum solvation model for water,
whereas the TM regions and the ligand atoms were held frozen.
Glide Docking Studies—The automatic docking program,
Glide (Schrodinger Inc.) was then used to first score the manual
docks and then explore other possible binding conformations
or receptor site interactions with flexible docking. Glide was
used to generate a grid based on the centroid of the ligand in the
binding site (from the manual docks). Any hydrophobic region
defined in the grid generation that contacted the ligand was
selected as important to the flexible docking procedure. The
box for flexible docking was defined large enough to encompass
Y3.32(96) as the primary interaction site for zaprinast and
R3.36(100) and R4.60(151) as primary interactions for pamoic
acid. Standard precision (SP) was selected, and flexible docking
was invoked unless scoring a manual dock (50).

RESULTS
GPR35 Receptor Model Development
A homology model of the GPR35 inactive state was developed using the ␤2-AR crystal structure (Protein Data Bank code
2RH1 (25)) as the template. This initial model was refined based
on sequence dictated differences between GPR35 and the
␤2-AR crystal structure. The key differences between these two
TMH bundles are described below.

TMH2
Like the CXCR4 receptor (30), GPR35 contains the XX(C/S/
T)LP motif in TMH2, with proline position at 2.58. This motif
creates a tightly wound proline kink where the C/S/T residues
in the proline kink region are in g(⫺), supporting the tightly
wound kink structure. The ␤2-AR has a relaxed broad turn in
the 2.59 proline kink region. The different turn ratio between
the ␤2-AR and the GPR35 TMH2 proline kink region supports
TMH2 fitting into the general seven-TMH GPCR structure, but
with a different set of residues facing into the binding site. For
example, residue V2.60 faces into the binding pocket of GPR35,
whereas residue 2.60 in the ␤2-AR structure (25) is in the
TMH2–3 interface and not available from within the binding
pocket. Another consequence of the Pro at 2.58 in GPR35 is
that the extracellular portion of TMH2 leans toward TMH3. It
is important to note that had the GPR35 TMH2 retained the
␤2-AR TMH2 conformation, the GPR35 EC1 loop would not
have been able to join the EC ends of TMH2 and TMH3,
because the GPR35 EC1 loop is only two amino acids long (SD).
In contrast, the EC1 loop of the ␤2-AR is six amino acids in
length (KMWTFG).
TMH4
GPR35 lacks the proline at 4.60 found in the ␤2-AR. CM
results suggest that the lack of this proline at 4.60 causes a local
change at the extracellular end of TMH4, which leans toward
TMH5 compared with the ␤2-AR crystal structure (Fig. 3).
TMH5
TMH5 in GPR35 has a proline at 5.50 and at 5.43. Because the
␤2-AR TMH5 has the conserved P5.50 as does GPR35 TMH5,
the backbone torsions for that Pro kink were preserved and only
the region around P5.43 in GPR35 TMH5 was explored via CM.
These calculations suggested that P5.43 leans the extracellular
end of TMH5 away from the binding crevice in GPR35. This
change is accommodated in GPR35 because the GPR35 EC2
loop is longer than ␤2-AR (GPR35 11 amino acids versus 5
amino acids in ␤2-AR).
TMH6
The CM output gives helices that bend inward toward the
binding crevice and also helices that bend toward TMH7. From
the helices generated by CM, we picked two helices, one that
would maintain the R3.50/T6.30 hydrogen bond TMH6 R (C-␣
to C-␣ distance ⫽ 6.15 Å) and one for which this interaction
would be broken. TMH6 R had the following bend, wobble, and
face shift angles: 32.8°, ⫺62.1°, and 129.5°. TMH6 R* had the
following bend, wobble, and face shift angles: 32.3°, ⫺71.2°, and
83.3°. The differences in these two conformers are in their wobble and face shift angles. These changes result in the intracellular end of TMH6 in R* pivoting away from the IC end of TMH3.

TMH1
Despite the presence of three glycines (G1.34, G1.30,
and G1.46) in TMH1, conformational memories calculations
revealed that TMH1 in GPR35 is similar to TMH1 in ␤2-AR,
which leans away from the TMH bundle on the extracellular
side.
FEBRUARY 7, 2014 • VOLUME 289 • NUMBER 6

TMH7
GPR35 TMH7 lacks the highly conserved class A GPCR
NPXXY motif, having instead DAICY. The lack of a proline
residue in TMH7 resulted in CM output that did not have the
usual proline induced bend and deformation seen in crystal
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. A comparison of the activated ␤2-AR crystal structure (37) (A) and the GPR35 R* (active) state model (B) is illustrated here. The receptors are
each shown from an extracellular view.

structures of other class A GPCRs. However, GPR35 has a
charged residue, K7.40, that faces toward TMH2 in the binding
pocket that should draw water into the TMH1-2-7 region. We
have shown previously for GPR55 that such charged residues
(D7.43 and D7.49 for GPR55) in TMH7 become hydrated, and
this water further perturbs the backbone structure on TMH7 by
hydrogen bonding to backbone carbonyls. The net result is a
region of 3–10 helix from 7.43 to 7.50.
GPR35 Model Activated Form (R*)
Fig. 3 illustrates a comparison of the activated ␤2-AR crystal
structure (37) (Fig. 3A) and the GPR35 active state model (Fig.
3B). Here the view is from the extracellular side of each receptor. One hallmark of GPCR activation is the breaking of the
ionic lock between R3.50 and E/D6.30 (T6.30 in GPR35), which
allows TMH6 to change conformation. The result is an intracellular opening of the receptor, exposing residues that can
interact with the C terminus of G␣ (51). The active form of the
GPR35 receptor model differs from the inactive form mainly in
changes at the intracellular side of the receptor. The intracellular end of TMH6 has changed conformation and moved its IC
end, breaking the hydrogen bond between R3.50 and T6.30.
The distance between the C␣ carbons of R3.50 and T6.30 is 11.8
Å in the GPR35 R* model, indicating loss of interaction between
the IC ends of TMH3 and TMH6. This distance is comparable
to the opening formed in the rhodopsin meta II (activated state)
crystal structure (R3.50 –E6.30 C␣ distance ⫽ 14.7 Å) (52) in
which the C-terminal fragment of G-␣ of transducin is inserted.
The size of this same opening in the nanobody stabilized ␤2-AR
crystal structure (Fig. 3A), is larger (R3.50 and E6.30 C␣ distance ⫽ 17.2 Å) (37), because of the physical insertion of the
nanobody higher than the C-terminal fragment of G-␣ of transducin, which causes the IC opening to enlarge.
GPR35 R6.58A Model Activated Form (R*)
To create the R6.58A mutant, residue 6.58 in the WT R*
bundle was mutated to Ala, and the bundle was reminimized.
This mutation did not change the overall conformation of
TMH6. The mutant TMH6 had the following bend, wobble,
and face shift angles: 32.7°, ⫺74.4°, and 83.1°. The distance
between the C␣ carbons of R3.50 and T6.30 in the R6.58A
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mutant R* model was 11.9 Å, indicating loss of interaction
between the IC ends of TMH3 and 6.
Ligand Conformational Analysis: Pamoic Acid Dianion
Pamoic acid (pKa1 ⫽ 2.51, pKa2 ⫽ 3.1) (53) is a dianion at
physiological pH. For this reason, pamoic acid was docked as
a dianion here. Conformational analyses were performed in
vacuo and in a SM8 water solvation model as implemented in
Spartan ’08. Both analyses yielded the same global minimum
energy conformer. In this conformation, the ring systems are
nearly perpendicular to each other (C2-C1-C1-C1⬘ ⫽
118.5°; C2⬘-C1⬘-C1-C1 ⫽ 118.3°) with the carboxyl (and
hydroxyl) groups pointing away from each other (for numbering system, see Fig. 2).
Docking Studies: Pamoic Acid
Pamoic Acid/Wild-type Human GPR35 R*—We used our
GPR35 activated state model to probe the nature of the interactions of pamoic acid dianion within the GPR35-binding
pocket. Pamoic acid dianion is both charged and highly aromatic. Docking studies suggested that the pamoic acid-binding
pocket is in the TMH3-4-5-6 region of GPR35. Fig. 4A illustrates the final docked pose of pamoic acid in the GPR35 R*
model (Glide score SP 5.0, ⫺8.81 kcal/mol). In this docked position, pamoic acid is able to form several highly favorable polar
interactions with Arg residues, including several salt bridges
and cation- interactions (residues colored magenta). The
ligand also forms hydrogen bonds (residues colored orange)
and predominantly van der Waals interactions with other residues (residues colored yellow). The geometries of these interactions are discussed below. Pamoic acid establishes a salt
bridge, as well as a hydrogen bond with the EC2 loop residue,
R(164). The N–O distances are 2.68 and 2.82 Å, and the
N–H—O angles are 166 and 162°, respectively. An additional
EC2 loop residue, R(167), forms a salt bridge with the other acid
moiety of the ligand. The N–O distance is 2.71 Å, and the
N–H—O angle is 161°. Pamoic acid also forms a salt bridge with
R3.36. The N–O distance is 2.63 Å, and the N–H—O angle is
164°. Q3.29 hydrogen bonds with this same carboxyl group having a N–O distance of 2.80Å and a N–H—O angle of 177°. R4.60
forms a parallel and a tilted T cation- interaction with the two
VOLUME 289 • NUMBER 6 • FEBRUARY 7, 2014
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due does not interact with pamoic acid. We created an R6.58A
GPR35 R* model to examine possible changes occurring upon
mutation. Fig. 4B illustrates the final docked pose of pamoic
acid in the GPR35 R* model (Glide score SP 5.0, ⫺8.95 kcal/
mol). In this docked position, pamoic acid is able to form several highly favorable polar interactions with Arg residues,
including several salt bridges and cation- interactions (residues colored magenta). The ligand also forms hydrogen bonds
(residues colored orange) and predominantly van der Waals
interactions with other residues (residues colored yellow). The
interactions that pamoic acid has in the R6.58A mutant are
identical to WT GPR35. R(164) has a salt bridge and a hydrogen
bond with one of the acid moieties of pamoic acid. The N–O
distances are 2.65 and 2.92 Å, and the N–H—O angles are 165
and 169°, respectively. Pamoic acid also forms a salt bridge with
R3.36. The N–O distance is 2.84 Å, and the N–H—O angle is
169°. Also, Q3.29 hydrogen-bonds with this same carboxyl
group having a N–O distance of 2.78 Å and a N–H—O angle of
161°. Residues S5.39 and R(167) have a hydrogen bond and a
salt bridge with the other acid moiety of pamoic acid. The
hydrogen bond O–O and salt bridge N–O distances are 3.03
and 2.63 Å, whereas the O–H—O and N–H—O angles are 162
and 165°, respectively. R4.60 forms a parallel and a tilted T
cation- interaction with the two sets of fused rings of pamoic
acid. The distance of the central carbon of the guanidinium of
R4.60 and the centroid of the ring that is parallel to the R4.60 is
3.96 Å. The distance and angle of the central carbon of the
guanidinium of R4.60 and the centroid of the ring that forms
the tilted T cation- interaction are 3.87 Å and 63°. Other
amino acids that have predominantly van der Waals interaction
energies with pamoic acid are T166, L6.55, and L3.33.
Ligand Conformational Analysis: Zaprinast

FIGURE 4. This figure illustrates the final docked poses of pamoic acid
dianion in the human WT GPR35 R* model (A) and in the R6.58A GPR35 R*
model (B). Residues that form salt bridge and cation- interactions are colored magenta, whereas residues that form hydrogen bonds are colored
orange, and residues that contribute mainly van der Waals interactions are
colored yellow. Residues that are not part of the ligand-binding pocket are
colored gray.

sets of fused rings of pamoic acid. The distance of the central
carbon of the R4.60 guanidinium group and the centroid of the
ring that is parallel to the R4.60 is 4.19 Å. The distance and angle
of the central carbon of the R4.60 guanidinium group and the
centroid of the ring that forms the tilted T cation- interaction
are 3.94 Å and 60°, respectively. The TMH residue, S5.39,
hydrogen-bonds with the other acid moiety of pamoic acid. The
hydrogen bond O–O distance is 2.70 Å, and the O–H—O angle
is 165°. The residues T166, L6.55, and L3.33 have van der Waals
interactions with pamoic acid dianion. Finally, R6.58 lies above
the pamoic acid-binding pocket and has no direct interactions
with pamoic acid (colored gray).
Pamoic Acid/Human R6.58A Mutant GPR35 R*—Despite
the fact that pamoic acid is predicted to dock in the arginine
rich TMH3-4-5-6 region of GPR35, not all of these arginines
appear to be necessary for ligand binding. A case in point is
R6.58. Our modeling studies (see above) suggest that this resiFEBRUARY 7, 2014 • VOLUME 289 • NUMBER 6

The zaprinast tautomer used for docking, 5-(2-propoxy-phenyl)-2,6-dihydro[1,2,3]-triazolo-[4,5-d]pyrimidin-7-one) was
the global minimum energy conformer for the 2,6-dihydro tautomeric state (see numbering system in Fig. 2). This tautomer
was 1.55 kcal/mol above the lowest energy tautomer global min
as calculated by Hartree-Fock, which was the 3,6-dihydro form.
Although this tautomer choice costs energy, the location of a
proton at N2 facilitates a key interaction with Y3.32, a residue
found to be important for zaprinast action at GPR35 (49) (see
“Discussion”). The global minimum energy conformer for this
tautomeric form of zaprinast has the two ring systems nearly in
plane with each other (C2⬘-C1⬘-C5-N6 ⫽ 16.1°) with the
2-propoxy group near N6 of the bicyclic ring (see Fig. 2 for
numbering system).
Docking Studies: Zaprinast
Zaprinast-GPR35 R* Complex—The EC50 of zaprinast is
considerably higher than that of pamoic acid. Docking studies
suggested that like pamoic acid, the binding pocket for zaprinast is in the TMH3-4-5-6 region of GPR35. Fig. 5A illustrates
the final docked pose of zaprinast in the GPR35 R* model (Glide
score SP 5.0, ⫺4.14 kcal/mol). Unlike pamoic acid, zaprinast is
not charged and therefore cannot form salt bridges like pamoic
acid. In its docked position, zaprinast is able to form hydrogen
bonds (residues colored orange) and predominantly van der
Waals interactions with other residues (residues colored yelJOURNAL OF BIOLOGICAL CHEMISTRY
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(colored gray) are above the zaprinast-binding pocket and have
no direct interaction with zaprinast.
Zaprinast-GPR35 R6.58A R* Complex
Fig. 5B illustrates the final docked pose of zaprinast in the
R6.58A GPR35 R* model (Glide score SP 5.0, ⫺5.38 kcal/mol).
Our modeling studies suggest that R6.58 in WT GPR35 does
not interact with zaprinast but produces crowding in the binding region. Removal of R6.58 via the R6.58A mutation is actually favorable for zaprinast because it acquires additional interactions compared with WT. In its docked position, zaprinast
is able to form hydrogen bonds (residues colored orange) as well
as predominantly van der Waals interactions with other residues (residues colored yellow). Zaprinast can form a hydrogen
bond between Q3.29 and the C⫽O oxygen of its fused ring
system. The N–O distance is 2.84 Å, and N–H—O angle is
143.5°. Additional contributors to the zaprinast interaction
energy come from residues that form predominantly van der
Waals interactions with the ligand. These include L6.55,
R(164), L3.33, and L6.51. Zaprinast also has two aromatic stacking interactions that add to its receptor interaction, one with
F5.47 and one with Y3.32. F5.47 forms a tilted T aromatic stack
with the propoxy-benzyl ring of zaprinast. The ring centroid to
centroid distance is 6.22 Å, and the angle of the planes of the
two rings is 50°. The fused ring system also stacks with F5.47.
The ring centroid to centroid distances of the five- and sixmember rings are 5.61 and 5.90 Å, respectively, and the plane to
plane angle is 59°. Y3.32 forms a tilted T interaction with the
fused ring system of zaprinast. The centroid to centroid distance of the two rings is 4.77 Å, and the plane to plane angle is
72°. R4.60 (colored cyan) forms a boundary of the zaprinastbinding pocket but does not have a significant interaction with
zaprinast. R(167) (colored gray) is above the zaprinast-binding
pocket and has no direct interaction with zaprinast.
Agonist-induced ␤-arr2-GFP Trafficking in Mutant GPR35 Cells

FIGURE 5. This figure illustrates the final docked poses of zaprinast in the
human WT GPR35 R* model (A) and in the R6.58A GPR35 R* model (B).
Residues that form hydrogen bonds are colored orange, and residues that
contribute mainly van der Waals interactions are colored yellow. Residues
that are not part of the ligand-binding pocket are colored gray, whereas residues that may form a boundary of the binding pocket are colored cyan.

low). The C⫽O oxygen of the zaprinast fused ring system can
form a hydrogen bond with R(164). The N–O distance is 2.64 Å,
and the N–H—O angle is 168°. Q3.29 is too far to hydrogenbond with zaprinast, but this residue has significant van der
Waals interactions with zaprinast. R4.60 (colored cyan) forms a
boundary of the zaprinast-binding pocket but does not have a
significant direct interaction with zaprinast. Several other
amino acids have predominantly van der Waals interactions
with zaprinast, including L3.33, L6.51, and L6.55. Y3.32 has a
tilted T aromatic stack with the heterocyclic fused ring of zaprinast. The distance is 4.14 and 5.65 Å for the five- and six-member rings, respectively, and the angle is 49°. R6.58 and R(167)
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Stable U2OS cell lines expressing both ␤-arr2-GFP and each
of the mutants as well as WT were made to assess agonistinduced receptor activation of ␤-arr2-GFP trafficking. Cell surface expression of the receptor was confirmed by HA immunostaining for WT, A4.59G, R4.60A, R6.58A, R(164)A/L, K7.40A
(Fig. 6), K1.32A, R2.65A, and R(167)A cell lines (data not
shown). Application of pamoic acid (1 M) or zaprinast (10 M)
induced the typical ␤-arr2-GFP aggregates in WT, A4.59G,
R(164)A/L, and K7.40A cell lines (Fig. 7) and K1.32A, R2.65A,
and R(167)A cell lines (data not shown). The R4.60A mutant
did not respond to treatment with pamoic acid or zaprinast.
Although R6.58A cells also showed ␤-arr2-GFP aggregates
upon pamoic acid or zaprinast treatment (Fig. 7), an abnormal
morphological change was observed. Treated R6.58A cells
rounded up, this made the ␤-arr2-GFP trafficking assay unreliable for this cell line.
HA immunostaining of the R3.36A and R7.33A (data not
shown) mutant U2OS cell lines showed no cell surface expression (Fig. 8A, left panels), but instead showed strong cytosolic
expression in permeabilized cells (Fig. 8A, second panels from
left). Immunostaining of HEK293 cells transiently transfected
with R3.36A plasmid also showed no surface expression but
strong cytosolic expression (Fig. 8A, right two panels). No
VOLUME 289 • NUMBER 6 • FEBRUARY 7, 2014
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FIGURE 6. Immunofluorescent confirmation of surface expressing of
GPR35 mutant receptors and cytosolic ␤arr2-GFP. Wild-type GPR35,
A4.59G, R4.60A, R6.58A, R(164)A, R(164)L, and K7.40A showed typical surface
receptor staining pattern using HA monoclonal antibody. All these mutant
cell lines showed ␤arr2-GFP expression similar to wild-type GPR35 cells. Scale
bars, 20 m.

␤-arr2-GFP response was observed in R3.36A mutant cells upon
pamoic acid or zaprinast treatment (Fig. 8B). To localize the cytosolic HA-tagged R3.36A mutant, U2OS cells expressing R3.36A
alone were permeabilized and immunostained with HA and the
ER-resident protein calrecticulin (18). High magnification of confocal images reveals a perinuclear labeling that is characteristic of
ER staining (Fig. 8C). Co-localization of the ER protein calreticulin
with the R3.36A GPR35 suggests that the R3.36A mutant is
retained intracellularly at the ER. This is consistent with the lack of
cell surface receptor immunoreactivity for R3.36A (Fig. 8A). Treatment of R3.36A U2OS cells with GPR35 antagonist CID2745687
(5) for 16 h rescued the surface expression of R3.36A, suggesting a
chaperone function by this antagonist.
To compare the potencies of these mutants, ␤-arr2-GFP
response was quantified as previously described (5). The WT
GPR35 has EC50 values for pamoic acid and zaprinast-induced
activation of 52 nM and 1.0 M, respectively (Table 1). The substitution of Ala4.59 with a glycine did not significantly change
the potency for ␤-arr2-GFP response (Fig. 9 and Table 1).
Although modest rightward shifts in the concentration response
curves were observed with the K7.40A mutant receptor for pamoic
acid and zaprinast (Fig. 9, A and B), they were not significantly
different from the WT GPR35 receptor (Table 1). Both R(164)A
and the R(164)L mutants showed a robust rightward shift in the
concentration response curves for pamoic acid and zaprinast (Fig.
9, C and D, and Table 1). There was no ␤-arr2-GFP response in the
R3.36A and R4.60A mutants (Table 1). The EC50 value of R6.58A
was not obtained because the morphological changes made the
quantification of aggregates unreliable.
Agonist-induced ERK1/2 Activation in Mutant GPR35 Cells
In addition to the ␤-arr2-GFP trafficking assay, agonist-induced ERK1/2 phosphorylation was used to examine the functional effects of GPR35 mutations. A downstream effector of
FEBRUARY 7, 2014 • VOLUME 289 • NUMBER 6

FIGURE 7. Agonist-mediated ␤arr2-GFP response in mutant GPR35 cells.
Stable U2OS cell lines co-expressing ␤-arr2-GFP and each of the GPR35
mutants were made to examine the receptor activity. Representative images
showed cells in vehicle control, pamoic acid (1 M), and zaprinast (10 M). No
␤-arr2-GFP trafficking was observed at control condition for all the cell lines. WT,
A4.59G, R6.58A, R(164)A, R(164)L, and K7.40A showed ␤-arr2-GFP aggregates
upon both pamoic acid and zaprinast application. R6.58A cells rounded up after
both pamoic acid and zaprinast treatment. R4.60A did not show ␤arr2-GFP
response in both pamoic acid and zaprinast treatments. Scale bar, 20 m.

GPR35 activation is the G protein-dependent ERK1/2 phosphorylation. It has been shown to be independent of the ␤-arrestin pathway (5). Table 2 summarizes the activities of ERK1/2
by pamoic acid and zaprinast from WT and mutant GPR35
receptors. The EC50 values of agonists, pamoic acid, and zaprinast on the mutants A4.59G and K7.40A were comparable and
not statistically different from the WT receptor. In contrast, a
⬃30-fold increase in the potency of zaprinast was observed in
the R6.58A mutant receptor (83 nM) compared with the wildtype GPR35 receptor (2.8 M). A modest increase in potency of
pamoic acid in R6.58A (16 nM) was observed as well, compared
with WT (62.3 nM).
Calcium Responses in Wild-type and Mutant GPR35 Cells to
Agonists
Because GPR35 is a Gi/o-coupled receptor, calcium is a
downstream effector. Calcium response curves of mutant
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 8. Expression of GPR35 mutant R3.36A in U2OS and HEK293 cells.
A, U2OS and HEK293 cells are co-transfected with HA-tagged R3.36A and
␤arr2-GFP. Cell surface staining of HA-tagged R3.36A did not show specific
signal in both U2OS and HEK-293 cells. HA staining of permeabilized cells
showed strong HA antibody signal in both U2OS and HEK-293. ␤arr2-GFP was
expressed in both U2OS and HEK-293 cells. B, transiently transfected U2OS cells
expressing both R3.36A and ␤-arr2 GFP were treated with vehicle control,
pamoic acid (10 M), and zaprinast (10 M). No difference between drug-treated
and control cells was observed in terms of ␤-arr2 GFP trafficking. C, co-localization
of HA and calreticulin in permeabilized U2OS cells transiently transfected with
HA-tagged R3.36A. D, CID2745687 rescued the surface expression of R3.36A. HA
staining is shown in red; DAPI staining is shown in blue. Scale bar, 20 m.

TABLE 1
␤arr2-GFP trafficking activities of wild-type and mutant cell lines

FIGURE 9. ␤-Arrestin2 and calcium responses of wild-type and mutant
GPR35 receptors. A, ␤-arrestin2 response of WT, A4.59G, and K7.40A to the agonist pamoic acid. B, ␤-arrestin2 response of WT, A4.59G, and K7.40A to the
agonist zaprinast. C, ␤-arrestin2 response of WT, R(164)A, and R(164)L
to the agonist pamoic acid. D, ␤-arrestin2 response of WT, R(164)A, and
R(164)L to the agonist zaprinast. E, calcium response of WT, R(167)A, and R6.58A
to the agonist pamoic acid. F, calcium response of WT, R(167)A, and R6.58A to the
agonist zaprinast. Each data point represents the mean ⫾ S.E. of at least three
independent experiments performed in quadruplicate.

TABLE 2
The effects of amino acid mutations of recombinant GPR35 on the
ERK1/2 activation induced by pamoic acid and zaprinast
ND, not detected; NT, not tested.

ND, not detected; NT, not tested.

EC50 (CI)
EC50 (CI)

a

Cell line

Pamoic acid

Zaprinast

WT
R3.36A
A4.59G
R4.60A
R6.58A
K7.40A
R(164)A
R(164)L
K1.32A
R2.65A
R(167)A
R7.33A

52.0 nM (33.8–80.0)
ND
55.7 nM (35.7–83.6)
ND
NT
111.3 nM (65.4–189.3)
783 nM (214–2859)a
944 nM (391–2277)a
29.7 nM (6.8–130.4)
43.2 nM (20.2–92.4)
200.5 nM (87.5–459.8)a
ND

1.0 M (0.7–1.3)
ND
0.9 M (0.5–1.6)
ND
NT
1.4 M (1.0–1.9)
5.2 M (3.0–9.0)a
6.1 M (1.6–23)a
1.4 M (0.5–4.4)
0.5 M (0.2–1.2)
1.6 M (0.9–2.7)
ND

p ⬍ 0.05. EC50 values and 95% confidence intervals are shown from n ⬎ 3
experiments.

R6.58A shifted to the left compared with WT (Fig. 9, E and F).
With zaprinast, the EC50 values were 0.3 M (0.25– 0.35 CI) for
WT and 0.038 M (0.034 – 0.044 CI) for R6.58A. With pamoic
acid, the EC50 values were 25 nM (21–28 CI) for WT and 6.0 nM
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Cell line

Pamoic acid

Zaprinast

WT
R3.36A
A4.59G
R4.60A
R6.58A
K7.40A

62.3 nM (30.5–127)
NT
45.6 nM (6.7–309)
ND
16.0 nM (6.6–38)
70.7 nM (23.2–215)

2.8 M (0.5–15)
NT
0.5 M (0.1–2.7)
ND
0.08 M (0.02–0.3)
0.5 M (0.22–1.1)

p ⬍ 0.05. EC50 values and 95% confidence intervals are shown from n ⬎ 3 experiments performed in triplicate.

(5.1– 6.9 CI) for R6.58A. On the contrary, the mutant R(167)A
showed right shifted curves, indicating lower potencies for agonists. The EC50 values were 69 nM (56 – 84 CI) for pamoic acid
and 1.2 M (1.0 –1.4) for zaprinast in the R(167)A mutant.
These shifts of potencies in the mutants are consistent with the
␤-arr2-GFP response (Table 1) and ERK1/2 activation (Table 2)
results. Quantification of receptor expression levels of WT and
mutants (Table 3) showed no significant difference between
them, indicating that the expression level is not a contributing
VOLUME 289 • NUMBER 6 • FEBRUARY 7, 2014
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TABLE 3
Quantification of receptor surface expression level of GPR35 and
mutants by HA antibody immunostaining
n ⱖ 4 images in each group.
Cell
line
WT
R(164)A
R(167)A
R6.58A

Immunostaining intensity
(mean ⴞ S.E.)
12.29 ⫾ 1.13
11.65 ⫾ 0.91
13.22 ⫾ 1.04
9.60 ⫾ 1.25

factor for the shifts of response curves of ␤-arr2-GFP, ERK1/2,
and calcium.

DISCUSSION
To date, there is no x-ray crystal structure information available for the human GPR35 receptor; thus, in the present study,
we have used computational modeling together with site-directed mutagenesis to explore the structural features of human
GPR35 involved in agonist-induced receptor activation. The
GPR35 sequence contains numerous positively charged amino
acids that face into the binding pocket. These residues cluster in
two distinct receptor regions: the TMH3-4-5-6 region and the
TMH1-2-7 region of GPR35 (Fig. 1).
The most prominent positively charged amino acid in the
TMH 1-2-7 region of the GPR35-binding pocket is K7.40,
whereas other positively charged residues that face into the
binding pocket but are more extracellular include K1.32, R2.65,
and R7.33. Mutation of each of these residues to Ala resulted in
the retention of WT EC50 for pamoic acid and zaprinast.
Because many of the ligands for GPR35 are anions, a lack of
change in potency for any of these TMH1-2-7 residues suggests
that the ligand-binding pocket of GPR35 may not lie in the
TMH 1-2-7 region of GPR35.
The majority of the positively charged residues that face into
the binding pocket are located in the TMH 3-4-5-6 region.
These residues include R3.36, R4.60, and R6.58 and the EC-2
loop residues R(164) and R(167). In contrast to results for the
TMH 1-2-7-binding pocket region, we found that mutation of
many of the positively charged binding site residues in the
TMH 3-4-5-6 region affected both pamoic acid and zaprinast
signaling. Fig. 10 illustrates the relative positions of pamoic acid
and zaprinast in their docked positions as determined by Glide
docking studies. In this view from lipid looking between TMH5
and TMH6, it is clear that both ligands bind in the same general
area (TMH3-4-5-6 region); however, their positions are shifted
relative to each other. Pamoic acid extends further up toward
extracellular space than does zaprinast and also moves closer to
TMH4.
Many of the interactions identified by docking studies, particularly for pamoic acid, are salt bridge and cation- interactions, which are strong interactions. It is important to emphasize, however, that the presence of water will have a dampening
effect on such electrostatic interactions. This would be particularly true for residues in loop regions but is likely true even for
transmembrane positively charged residues here, because the
high concentration of positively charged residues in the
GPR35-binding pocket likely draws waters down into the binding pocket. One therefore cannot expect as profound a change
FEBRUARY 7, 2014 • VOLUME 289 • NUMBER 6

FIGURE 10. The relative positions of pamoic acid (blue) and zaprinast
(orange) in their docked conformations as determined by Glide docking
studies. In this view from lipid looking between TMH5 and TMH6, it is clear
that both ligands bind in the same general area (TMH3-4-5-6 region); however, their positions are shifted relative to each other. Pamoic acid extends
further up toward extracellular space than does zaprinast and pamoic acid
also moves closer to TMH4.

upon mutation and loss of a salt bridge in GPR35 compared
with other receptors that may have an analogous salt bridge
shielded from water.
Many of the mutations performed here had very striking
effects. The EC-2 loop residue R(164) is shown here by mutation and modeling studies to be a key interaction site for pamoic
acid, with a significant increase in EC50 values (R164A 15-fold;
R164L, 18-fold) upon mutation to an uncharged residue. R(164)
forms a hydrogen bond, rather than a salt bridge, with zaprinast. Mutation of R(164) to an uncharged amino acid would be
expected, therefore, to have a less profound effect on the EC50
of zaprinast when compared with the effect of this mutation on
pamoic acid. The 5-fold increase in EC50 for zaprinast at the
R(164)A and R(164)L mutants, therefore, is consistent with this
result.
R(167) in the EC2 loop is also shown here by modeling and
mutation studies to be a key interaction for pamoic acid, but not
for zaprinast. R(167) forms a salt bridge with the part of pamoic
acid that is located near the extracellular end of TMH5. This
interaction is with the carboxyl group with which R(164) does
not interact. The R(167) interaction with pamoic acid is shown
to be weaker by mutation studies than the R(164) interaction
but still significant with an increase in EC50 of almost 4-fold for
pamoic acid. Zaprinast does not interact with R(167), as shown
by modeling, because zaprinast is located further from TMH5.
Because the position of zaprinast does not shift toward TMH5
in the R6.58A mutant, no interaction with R(167) is present
there as well.
Our modeling studies suggest that at the pamoic acid binding
site, R4.60 forms a parallel and a tilted T cation- interaction
with both fused rings of pamoic acid. Although R4.60 does not
form a very high energy interaction with zaprinast, this residue
forms the boundary of the zaprinast-binding pocket and therefore could be anticipated to play an important structural role in
the zaprinast-GPR35 R*-binding pocket (Fig. 5). We show here
that mutation of Arg4.60 to alanine abolished the agonist-inJOURNAL OF BIOLOGICAL CHEMISTRY
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duced receptor activation for both pamoic acid and zaprinast
and in two independent assays of ␤-arr2-GFP trafficking and
ERK1/2 phosphorylation. This suggests that R4.60(151) is a
key residue in the GPR35 R*-binding pocket that may serve
to initially align the ligand in the binding pocket either
through direct coulombic interactions via a cation- interaction (pamoic acid) or by defining one edge of the binding
pocket (zaprinast).
R6.58 is located near the extracellular end of TMH6 and
points toward the TMH3-4-5-6 region of GPR35. Our modeling studies suggest that this residue does not directly interact
with pamoic acid and that the interactions that pamoic acid has
in the R6.58A mutant receptor are almost identical, with the
exception of the exchange of a direct interaction with Q(157)
for R(167). The R6.58A mutation does not cause a large drop in
the overall interaction energy of pamoic acid, because interaction with other residues (principally T(166)) improves in the
absence of R6.58. Thus, modeling would predict that the
R6.58A mutation should have little effect on the efficacy of
pamoic acid.
Our modeling studies suggest that R6.58 does not interact
with zaprinast either but produces crowding in the binding
region. Removal of R6.58 via the R6.58A mutation is actually
favorable for zaprinast. The improved receptor interaction
results from multiple stronger interactions at L6.55, R(164),
L3.33, and L6.51. In each case, the gains are largely due to
improved van der Waals interactions. Thus, modeling would
predict that zaprinast should have a lower EC50 in the R6.58A
mutant.
Mutation studies showed that R6.58A increases the potency
of zaprinast in the pERK assay. On the other hand, it causes a
roundup of cells upon agonist treatment in the ␤-arr2-GFP
trafficking assay. Because of these morphological changes upon
agonist application, a reliable quantification of arrestin trafficking could not be obtained for this mutant. This morphological
change upon agonist application was not observed in WT and
other mutant cell lines. Interestingly, the calcium response
assay showed increased potencies for both zaprinast and
pamoic acid in the 6.58A mutant, similar to what was observed
in the pERK assay.
Modeling studies suggest that R3.36 is a major contributor to
the interaction energy of pamoic acid at GPR35 R*. This residue
also interacts with zaprinast, but in a lower energy interaction.
An R3.36A mutation can be expected to impact both ligands,
but pamoic acid more significantly. Mutation of Arg3.36 to alanine prevented GPR35 receptor expression on the cell surface;
it was trapped in the endoplasmic reticulum. This suggests that
R3.36A mutation may cause a structural misfolding during the
protein maturation process. This is consistent with the ability
of the GPR35 antagonist to rescue cell surface expression of
R3.36A (Fig. 8D). A similar chaperone function by ligands has
been previously documented for V2 vasopressin receptor (18).
In the functional assay, there was no ␤arr2-GFP trafficking
response for this mutant upon pamoic acid and zaprinast application. Lack of ␤arr2 recruitment response for the mutant
R3.36A was reported in another study as well (49). The total loss
of ␤arr2 response for R3.36A may be due to the lack of surface
expression. Milligan and co-workers (49) have reported that the
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R3.36A mutation abolished ␤arr2 recruitment in response to
several GPR35 agonists. A recent mutant and modeling study
by MacKenzie et al. (54) also indicated the contributions of
R4.60, R(164), and R6.58 to ligand binding.
The A4.59G mutant is a random mutation created as a control. This residue actually faces lipid in the GPR35 R* model.
Mutation studies show here that this mutation did not change
the EC50 of pamoic acid or zaprinast relative to WT.
The Milligan group has reported that Y3.32 is also an important residue for the action of zaprinast (49). Modeling studies
reported here suggest that Y3.32 is a part of both the pamoic
acid- and zaprinast-binding pockets at GPR35 R*, with its interaction being stronger for zaprinast. In the present study, however, function in response to pamoic acid or zaprinast could not
be detected at a human Y3.32L mutant.
Our data strongly support that direct interactions of the
ligands with the mutated residues is responsible for the
observed functional effects. However, in the absence of radioligand binding experiments, direct interactions are implied and
not proven at this point. A recent mutant and modeling study
by MacKenzie et al. (54) also indicated the contributions of
R4.60, R(164), and R6.58 to ligand binding using functional
assays.
Recently it was reported that zaprinast is 38-fold more potent
for rat GPR35 than human GPR35 (55). Kynurenic acid also has
a higher potency for rat than human GPR35 (15). These findings imply that the ligand-binding site in human versus rat
might be distinct. The origins of this difference are currently
under investigation.
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